Function: Atypical antipsychotics, also known as the new generation of antipsychotics, are antipsychotics whose blockade of dopamine D2 receptors is weaker than that of 5-HT2A receptors, such as clozapine, lisinoprilone, olanzapine, quetiapine, and ziprasidone, all of which are currently in clinical use. Atypical antipsychotics, with the exception of clozapine, have been in clinical use since the 1970s. Atypical antipsychotics not only block dopamine D2 receptors, but also have the effect of blocking 5-HT2A receptors more strongly. When blocking dopamine D2 receptors in the mesolimbic- limbic pathway, they improve positive symptoms; when blocking 5-HT2A receptors on the presynaptic membrane of the mesolimbic-cortical pathway, they cause deinhibitory release of dopamine from the Chemicalbook, agonise dopamine D1 receptors in the dorsolateral prefrontal cortex, improve negative, cognitive symptoms, agonise dopamine D1 receptors in the dorsal-medial part of the prefrontal cortex and orbital region, and improve depressive symptoms; and when blocking dopamine D2 receptors in the dorsal-medial part of the prefrontal cortex and orbital region, improve depressive symptoms. When 5-HT2A receptors on the presynaptic membrane of the substantia nigra-striatum pathway are blocked, dopamine disinhibitory release is induced, which can partially counteract the drug's blockade of dopamine D2 receptors, so the extrapyramidal reaction is mild (and prolonged use is not likely to cause delayed dyskinesia); when 5-HT2A receptors on the presynaptic membrane of the hypothalamus-funnel are blocked, dopamine disinhibitory release is induced, which partially counteracts the drug's blockade of dopamine D1 receptors. release, partially counteracting the drug's blockade of dopamine D2 receptors, so hyperprolactinaemia is not obvious.